The signal

Somewhere in a US Air Force C-17 right now, there is a refrigerator. It is the size of a footlocker, it weighs about three hundred pounds with its battery pack, and the only thing inside it is human blood. Refrigerated O-negative is the most logistically expensive cargo the Air Force carries on a per-pound basis. It expires faster than fresh fish. It has to be cold-chained from a donor in Missouri to a forward operating base in five days or it goes in the trash.

A pediatric ICU doctor named Allan Doctor has a different idea: put the blood in a Ziploc bag.

That is a slight oversimplification. The actual idea is a tan-colored powder in a sealed pouch that a medic can mix with sterile water and run into a patient’s arm fifteen seconds later. No refrigeration. No type-matching. Shelf life measured in years, not days. Doctor — yes, that is his name — has been pitching this for a decade. He calls it instant blood. NASA has called him about putting it on a Mars mission. The Pentagon has now called him with a check.

What is interesting from this seat is that the patent record shows Doctor is not alone. Three different companies, working out of three different cities, using three different physical engineering approaches, have all converged on the same object: a vial of room-temperature blood substitute that goes in a backpack. And the trickle of filings out of the US patent office has turned into a small flood in the last twenty-four months.

What the patent record shows

Combine the granted US patents from Cellphire, KaloCyte, Haima Therapeutics, and the Case Western Reserve lab that spun out Haima, and you get 25 grants between 2020 and 2025 — for an industry that essentially didn’t exist outside a few academic labs in 2015. Cellphire alone has been granted six US patents in 2025 so far. KaloCyte just got its first major composition-of-matter grant in March. Haima and Case Western together have eight in the last three years.

The patents themselves are interesting because they describe three completely different molecular strategies for the same target:

• Cellphire (Rockville, MD) is making the human platelet itself shelf-stable. US 12,295,972, granted May 13, 2025, describes taking real donor platelets, washing them in a bath of trehalose and polysucrose — sugars that some desert organisms use to survive desiccation — running them through tangential-flow filtration, freeze-drying them, and then dry-heat-sterilizing the resulting powder at 60–90 °C. The product is called Thrombosomes. You add saline and it goes in a vein.
• Case Western Reserve / Haima Therapeutics (Cleveland) skipped the donor entirely. US 12,161,698, granted December 10, 2024, describes a “synthetic platelet” — a tiny liposome with three different peptides stuck on its outside. One peptide grabs collagen. One grabs von Willebrand factor. One grabs the surface of any platelet that has already started clotting. In other words: a particle that does what a platelet does to a wound, without ever having been a cell. The ratio of the three peptides is specified to one digit. The lab has been refining this for nearly two decades.
• KaloCyte (Baltimore) is replacing red cells instead of platelets. US 12,257,289, granted March 25, 2025, claims a self-assembling vesicle built from phospholipid, cholesterol, hemoglobin, and an allosteric effector. The vesicle ferries oxygen. A pH-responsive lipid in the membrane shifts oxygen affinity automatically when the cargo reaches acidic tissue, mimicking the Bohr effect of an actual erythrocyte. Freeze-dry the whole thing and you have powder.

Three different molecular tricks. One physical product. Sealed pouch, dry powder, no fridge.

Who’s writing the check

The reason these three labs are suddenly publishing on the same axis is that the Defense Advanced Research Projects Agency has decided the cold chain is a war-stopper. In 2023, DARPA stood up a four-year, $46.4 million program called Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products — FSHARP. Doctor is the principal investigator. The University of Maryland School of Medicine is the lead institution. The consortium includes Case Western Reserve, Ohio State, the University of Pittsburgh, Charles River Laboratories, Haima Therapeutics, KaloCyte, and the medical-device firm Teleflex, which is contributing a freeze-dried plasma product. The DARPA program manager is Robert Murray, out of the Biological Technologies Office.

The deliverable is one product, not three. ErythroMer carries the oxygen. SynthoPlate stops the bleeding. Teleflex’s plasma provides the volume and the clotting factors that platelets need to do their job. The DARPA brief, in its own words, asks for “deployable, shelf-stable” formulations of a “universal whole blood substitute” tailorable to different injury profiles — traumatic brain injury, coagulopathy, and so on.

Why now? Doctor has been making the case for years and the number he keeps citing is the one that matters: roughly 30,000 Americans bleed to death every year before they reach a hospital. Most of them are inside the so-called golden hour and could have been saved if a paramedic had been able to transfuse them at the scene. Right now, almost no civilian ambulance carries blood, because almost no civilian ambulance can afford to throw away a $400 unit every five days. Helicopter EMS programs that do carry blood spend more on its logistics than on its acquisition.

Cellphire is the one closest to a label. On October 1, 2025, the company announced that its CRYPTICS trial — a randomized study of its cryopreserved-platelet product CLPH-511 in cardiopulmonary bypass surgery — had hit its primary endpoint, with chest-tube drainage at 24 hours statistically non-inferior to fresh liquid platelets. The contract paying for that trial was W81XWH20C0030, out of the Defense Health Agency. Cellphire’s chief medical officer Damien Bates said the company would now go talk to the FDA.

The “so what” if it actually works

Three things change if any of these products clear an FDA approval.

Pre-hospital trauma stops being a cold-chain problem. Helicopter EMS, military medics, rural ambulances, oil-rig clinics, cruise ships, and offshore platforms all currently triage hemorrhage with crystalloid IV fluid, which keeps a patient’s blood pressure up but dilutes their remaining red cells and clotting factors. Powder you reconstitute on the way to the hospital is a fundamentally different intervention. Doctor’s claim — that transfusion in the field would save tens of thousands of US lives a year — is conservative if you take seriously the number of people who currently die from preventable hemorrhage.

The blood-supply economics flip. A US hospital today spends roughly $200–$400 per unit of platelets and discards a high single-digit percent of inventory to expiration. A shelf-stable platelet product, if priced anywhere near parity, eliminates the discard line entirely and lets a rural hospital stock platelets at all — most cannot, today. The American Red Cross runs the largest cold chain in American medicine, and parts of it become obsolete.

The military supply line gets shorter. A frozen-platelet pouch is air-droppable, submarine-stowable, and survives 2027’s Pacific logistics scenarios in a way that refrigerated O-negative does not. This is the use case that gets the check signed, and it is also why DARPA picked four years as the deadline rather than ten.

The tell

The most interesting line in the Cellphire patent is the dry-heat sterilization step. Real platelets do not, as a rule, enjoy being heated to 80 °C for an hour. The reason the company can do that to its product and have it still work is that it isn’t quite a platelet anymore — it is a platelet derivative, structured to retain hemostatic function while being treatable like a piece of dry chemistry. That is the engineering move the entire field is making. A red cell is a delicate membranous sack. A platelet is a delicate membranous fragment. Both have evolved to operate in 37 °C plasma. The trick is to keep the function a platelet performs at a wound — recognize collagen, stick to von Willebrand factor, recruit other platelets — while detaching that function from the fragile cell that performs it in nature.

Doctor’s vesicles, Sen Gupta’s peptide-decorated liposomes, and Cellphire’s lyophilized derivatives are different chemistries of the same underlying engineering move: take a biological function, peel it off the biology, and re-host it on something a medic can ship in a Pelican case.

In ten years there is a non-trivial chance that the refrigerator in the back of that C-17 is gone, and the patent record is the place that signal has been showing up first.

Method note

US patent counts come from the public USPTO weekly grant feed (2010–2026 grants only, indexed locally). Assignee counts roll up corporate variants and university affiliates by name match; the 25-patent total includes Cellphire, KaloCyte, Haima Therapeutics, and Case Western Reserve patents whose titles or abstracts mention platelets or hemostasis. The FSHARP program details come from DARPA’s program page and the University of Maryland School of Medicine announcement (February 2023). The CRYPTICS trial topline result comes from Cellphire’s October 1, 2025 press release. Clinical-trial dates and phase information come from ClinicalTrials.gov. Doctor’s quotes on “instant blood” and the Mars mission inquiry come from a CBS Baltimore feature and his published interviews with Science and MPower Maryland. The “30,000 Americans per year” figure is Doctor’s, and is in the range of public CDC estimates for prehospital hemorrhagic deaths. Cellphire patent counts are for grants only (not pre-grant publications).